Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement

• Published in: Frontiers in endocrinology (Lausanne) Vol. 12; p. 739875
• Main Authors: Huang, Zhimin, Ng, Kaka, Chen, Hongyan, Deng, Wanping, Li, Yanbing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 31.01.2022
• Subjects: Biomarkers; Body Mass Index; controlled attenuation parameter (CAP); diabetes mellitus; Elasticity Imaging Techniques; Endocrinology; Female; FibroScan; Humans; insulin resistance; Male; Metabolic Diseases - diagnostic imaging; metabolic syndrome (MetS); Metabolic Syndrome - diagnostic imaging; Middle Aged; non-alcoholic fatty liver disease (NAFLD); Non-alcoholic Fatty Liver Disease - diagnostic imaging; non-alcoholic fatty liver disease (NAFLD); FibroScan; diabetes mellitus; controlled attenuation parameter (CAP); metabolic syndrome (MetS); insulin resistance
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2021.739875

Renaming non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) suggests a shift of emphasis to the accompanying metabolic disturbance. Controlled attenuation parameter (CAP) measured by FibroScan has been shown to be correlated with hepatic steatosis. We aim to validate its usefulness as a novel surrogate marker for evaluating metabolic derangement. Volunteers were recruited from medical staff at our hospital to undergo CAP measurements. Anthropometrics, CAP, and laboratory assessments for metabolic profiles and insulin resistance were collected. CAP < 238 dB/m denoted no hepatic steatosis, 238 ≤ CAP ≤ 259 dB/m denoted mild, 260 ≤ CAP ≤ 291 dB/m denoted moderate, and CAP > 291 dB/m denoted severe hepatic steatosis according to previous reports. Data of 824 participants were included for analysis. The age was 53.2 ± 15.4 years, body mass index (BMI) was 23.6 ± 3.1 kg/m , 24.4% were male subjects, and 22.0% met the criteria for metabolic syndrome (MetS). Taking the group with CAP < 238 dB/m as control, subjects with mild, moderate, and severe hepatic steatosis had increased odds of MetS by 3.51-, 3.32-, and 5.12-fold, respectively, after adjusting for multiple confounders ( = 0.020). Metabolic profiles, insulin resistance, and presence of MetS were similar between normal-weight subjects with CAP ≥ 238 dB/m and overweight subjects with CAP < 238 dB/m. Even in subjects with no MetS components, those with CAP ≥ 238 dB/m had higher BMI, waist circumferences, uric acid, triglyceride, white blood cell count, and insulin resistance, whereas lower adiponectin and estimated glomerular filtration rate. Waist circumference [OR 1.11 (1.04, 1.18), = 0.001] and homeostatic model assessment of insulin resistance (HOMA-IR) [OR 2.39 (1.18, 4.83), = 0.016] were predictive of hepatic steatosis according to CAP ≥ 238 dB/m. CAP is a convenient, sensitive, and non-invasive indicator for metabolic derangement. Prospective studies are needed to further validate its usefulness as a surrogate marker for the transition of metabolic status over time.